Aliases & Classifications for Lentigines

MalaCards integrated aliases for Lentigines:

Name: Lentigines 56 54
Lentigo 71

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
lentigines:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 56 150900
MedGen 41 C0023321
UMLS 71 C0023321

Summaries for Lentigines

MalaCards based summary : Lentigines, also known as lentigo, is related to acral lentiginous melanoma and noonan syndrome with multiple lentigines. An important gene associated with Lentigines is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Aminolevulinic acid and Vitamin A have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and heart, and related phenotypes are nystagmus and abnormality of the skin

Wikipedia : 74 A lentigo (/lɛnˈtaɪɡoʊ/) (plural lentigines, /lɛnˈtɪdʒɪniːz/) is a small pigmented spot on the skin with... more...

More information from OMIM: 150900

Related Diseases for Lentigines

Diseases related to Lentigines via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 acral lentiginous melanoma 34.5 MLANA KIT BRAF
2 noonan syndrome with multiple lentigines 34.4 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
3 leopard syndrome 2 33.7 RAF1 PTPN11
4 noonan syndrome 1 32.0 TYR RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
5 melanocytic nevus syndrome, congenital 31.7 TYR STK11 PRKAR1A MC1R CNC2
6 carney complex variant 31.5 STK11 PRKAR1A POMC MLANA MEN1 CNC2
7 hypertelorism 30.8 RAF1 PTPN11 FGFR2 BRAF
8 pulmonary valve stenosis 30.7 PTPN11 MAP2K2 MAP2K1
9 lentigo maligna melanoma 30.6 MLANA MITF MC1R
10 mucosal melanoma 30.6 MITF KIT BRAF
11 pigmented basal cell carcinoma 30.4 MLANA MITF
12 actinic keratosis 30.2 TYR MITF MC1R
13 neurofibromatosis-noonan syndrome 30.2 PTPN11 MAP2K2 MAP2K1
14 dowling-degos disease 1 30.1 TYR STK11 POMC MITF KIT
15 skin melanoma 30.1 TYR MLANA MITF MC1R KIT BRAF
16 neurofibromatosis, type i 30.1 PTPN11 MEN1 KIT
17 peutz-jeghers syndrome 30.0 STK11 PRKAR1A CNC2
18 adenoma 30.0 PRKAR1A POMC MEN1 BRAF
19 clear cell sarcoma 30.0 MLANA MITF KIT
20 skin carcinoma 30.0 TYR POMC MLANA MC1R
21 halo nevi 30.0 TYR MLANA
22 melanoacanthoma 30.0 TYR MLANA
23 mastocytosis 29.9 PTPN11 MITF KIT
24 gastrointestinal stromal tumor 29.9 RAF1 MEN1 KIT BRAF
25 hypertrophic cardiomyopathy 29.8 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
26 growth hormone secreting pituitary adenoma 29.8 PRKAR1A POMC MEN1
27 nodular malignant melanoma 29.8 TYR MLANA MITF MC1R KIT BRAF
28 pulmonic stenosis 29.8 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
29 rasopathy 29.8 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
30 neurofibroma 29.7 TYR MLANA MITF KIT
31 multiple endocrine neoplasia 29.6 PRKAR1A MEN1 CNC2
32 vitiligo-associated multiple autoimmune disease susceptibility 1 29.5 TYR POMC MLANA MITF MC1R
33 skin disease 29.4 TYR MITF MC1R FGFR2 FGF7
34 acromegaly 29.4 PRKAR1A POMC MEN1 CNC2
35 amelanotic melanoma 29.3 TYR MLANA MITF KIT BRAF
36 melanoma 29.3 TYR STK11 RAF1 MLANA MITF MC1R
37 primary pigmented nodular adrenocortical disease 29.2 PRKAR1A POMC MEN1 CNC2
38 conn's syndrome 29.1 PRKAR1A POMC MEN1 CNC2
39 microphthalmia 28.7 TYR POMC MLANA MITF MC1R KIT
40 waardenburg's syndrome 28.5 TYR POMC MITF KIT EDNRB
41 neurilemmoma 28.5 TYR PRKAR1A MLANA MITF KIT CNC2
42 melanoma, cutaneous malignant 1 28.0 TYR STK11 RAF1 MLANA MITF MC1R
43 leopard syndrome 1 12.2
44 gastrocutaneous syndrome 12.1
45 leopard syndrome 3 12.0
46 lentiginosis, inherited patterned 11.6
47 phacomatosis pigmentokeratotica 11.5
48 phakomatosis pigmentokeratotica 11.5
49 dyschromatosis universalis hereditaria 1 11.5
50 uv-sensitive syndrome 11.3

Graphical network of the top 20 diseases related to Lentigines:



Diseases related to Lentigines

Symptoms & Phenotypes for Lentigines

Human phenotypes related to Lentigines:

31
# Description HPO Frequency HPO Source Accession
1 nystagmus 31 HP:0000639
2 abnormality of the skin 31 HP:0000951

Symptoms via clinical synopsis from OMIM:

56
Eyes:
nystagmus

Skin:
lentigines

Clinical features from OMIM:

150900

GenomeRNAi Phenotypes related to Lentigines according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.55 BRAF
2 Decreased viability GR00055-A-2 9.55 BRAF
3 Decreased viability GR00221-A-1 9.55 KIT RAF1
4 Decreased viability GR00221-A-2 9.55 RAF1
5 Decreased viability GR00221-A-4 9.55 BRAF
6 Decreased viability GR00249-S 9.55 BRAF FGFR2
7 Decreased viability GR00301-A 9.55 BRAF FGFR2 KIT RAF1
8 Decreased viability GR00342-S-1 9.55 FGFR2
9 Decreased viability GR00342-S-2 9.55 FGFR2
10 Decreased viability GR00342-S-3 9.55 FGFR2
11 Decreased viability GR00381-A-1 9.55 BRAF
12 Decreased viability GR00402-S-2 9.55 RAF1
13 Decreased substrate adherent cell growth GR00193-A-1 9.5 STK11
14 Decreased substrate adherent cell growth GR00193-A-2 9.5 FGFR2
15 Decreased substrate adherent cell growth GR00193-A-3 9.5 BRAF FGFR2 MAP2K2 STK11
16 Decreased substrate adherent cell growth GR00193-A-4 9.5 BRAF
17 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.46 BRAF FGFR2 MAP2K2 RAF1

MGI Mouse Phenotypes related to Lentigines:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.52 BRAF EDNRB FGF7 FGFR2 KIT MAP2K1
2 cardiovascular system MP:0005385 10.5 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
3 cellular MP:0005384 10.5 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
4 behavior/neurological MP:0005386 10.48 BRAF EDNRB FGF7 FGFR2 KIT MAP2K2
5 craniofacial MP:0005382 10.46 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
6 integument MP:0010771 10.45 BRAF EDNRB FGF7 FGFR2 KIT MAP2K1
7 endocrine/exocrine gland MP:0005379 10.44 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
8 homeostasis/metabolism MP:0005376 10.44 BRAF EDNRB FGF7 FGFR2 KIT MAP2K1
9 embryo MP:0005380 10.42 BRAF EDNRB FGFR2 KIT MAP2K1 MEN1
10 immune system MP:0005387 10.4 BRAF EDNRB FGF7 FGFR2 KIT MC1R
11 hematopoietic system MP:0005397 10.39 BRAF EDNRB FGF7 FGFR2 KIT MC1R
12 mortality/aging MP:0010768 10.39 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
13 hearing/vestibular/ear MP:0005377 10.32 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
14 neoplasm MP:0002006 10.32 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
15 digestive/alimentary MP:0005381 10.31 BRAF EDNRB FGFR2 KIT MAP2K1 MAP2K2
16 nervous system MP:0003631 10.27 BRAF EDNRB FGF7 FGFR2 KIT MAP2K1
17 liver/biliary system MP:0005370 10.22 BRAF FGFR2 KIT MEN1 MITF POMC
18 adipose tissue MP:0005375 10.18 BRAF FGFR2 MAP2K2 POMC PRKAR1A PTPN11
19 normal MP:0002873 10.18 BRAF FGFR2 KIT MAP2K1 MAP2K2 MITF
20 no phenotypic analysis MP:0003012 10.17 FGFR2 KIT MC1R MITF MLANA POMC
21 muscle MP:0005369 10.15 BRAF EDNRB FGFR2 KIT MEN1 PRKAR1A
22 limbs/digits/tail MP:0005371 10.14 BRAF EDNRB FGFR2 KIT MC1R MITF
23 pigmentation MP:0001186 10.11 BRAF EDNRB FGFR2 KIT MC1R MITF
24 reproductive system MP:0005389 10 BRAF FGF7 FGFR2 KIT MAP2K1 MEN1
25 renal/urinary system MP:0005367 9.97 BRAF EDNRB FGF7 FGFR2 KIT MITF
26 skeleton MP:0005390 9.77 BRAF EDNRB FGF7 FGFR2 KIT MAP2K1
27 respiratory system MP:0005388 9.76 BRAF EDNRB FGFR2 KIT PRKAR1A PTPN11
28 vision/eye MP:0005391 9.44 BRAF EDNRB FGF7 FGFR2 KIT MAP2K1

Drugs & Therapeutics for Lentigines

Drugs for Lentigines (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4 106-60-5 137
2
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
3 Dermatologic Agents Phase 4
4 Photosensitizing Agents Phase 4
5 Retinol palmitate Phase 4
6 retinol Phase 4
7 Arnica Phase 4
8 Methyl 5-aminolevulinate Phase 4
9
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
10 Adjuvants, Immunologic Phase 2, Phase 3
11 interferons Phase 2, Phase 3
12 Immunologic Factors Phase 2, Phase 3
13
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 2 67-73-2 6215
14
Hydroquinone Approved, Investigational Phase 2 123-31-9 785
15
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
16
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
17
Cediranib Investigational Phase 2 288383-20-0 9933475
18
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
19 Vitamins Phase 2
20 Keratolytic Agents Phase 2
21 Protein Kinase Inhibitors Phase 2
22
Ganciclovir Approved, Investigational Phase 1 82410-32-0 3454
23 Antiviral Agents Phase 1
24 Ganciclovir triphosphate Phase 1
25 Anti-Infective Agents Phase 1
26
Neomycin Approved, Vet_approved 1404-04-2 8378
27
Clobetasol Approved, Experimental, Investigational 25122-41-2, 25122-46-7 32798 5311051
28
Tazarotene Approved, Investigational 118292-40-3 5381
29
Ethanol Approved 64-17-5 702
30
Glycolic acid Approved, Investigational 79-14-1 757
31
Desonide Approved, Investigational 638-94-8 5311066
32
Lidocaine Approved, Vet_approved 137-58-6 3676
33
Prilocaine Approved 721-50-6 4906
34
Tetracaine Approved, Vet_approved 94-24-6 5411
35
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
36 Anti-Bacterial Agents
37 Antibiotics, Antitubercular
38 Hormone Antagonists
39 Hormones
40 glucocorticoids
41 Anti-Inflammatory Agents
42 Pharmaceutical Solutions
43 Sodium Channel Blockers
44 Anti-Arrhythmia Agents
45 Anesthetics
46 Anesthetics, Local
47 Diuretics, Potassium Sparing
48 Chlorhexidine gluconate
49 Hemostatics

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 The Comparison of Picosecond 532 and 1,064 Nanometers Laser and Q-switched Nd:YAG 532 and 1,064 Nanometers Laser in the Treatment of Benign Pigmented Lesions: A Randomized Controlled Trial Unknown status NCT02800525 Phase 4
2 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
3 Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
4 Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula;Non-active placebo control
5 Treatment of Photodamaged Skin of the décolleté With Fractional Laser, Radio-frequency Microneedling, and Photodynamic Therapy Recruiting NCT03573076 Phase 4
6 A Randomized, Double-Blind, Placebo-Controlled Trial of Methyl Aminolevulinate + Aktilite in Patients With Facial Photodamage Completed NCT00629317 Phase 3 Methyl Aminolevulinate
7 Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin Completed NCT02204436 Phase 3
8 A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails Recruiting NCT02394132 Phase 3 Imiquimod
9 An Open Monocentric Pilot Study to Investigate the Potential of Imiquimod 5% Cream to Detect Residual and to Prevent Recurrence of Lentigo Maligna After Surgical Excision Active, not recruiting NCT01088737 Phase 2, Phase 3 Imiquimod
10 Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face Active, not recruiting NCT01720407 Phase 3 Imiquimod cream + surgery;Placebo + surgery
11 Phase 2 Study of the Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging Unknown status NCT02126644 Phase 2 70% glycolic acid
12 Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial. Completed NCT00975312 Phase 2 Triple combination cream;Tretinoin 0.05%
13 Efficacy and Side Effects of Q-Switched Ruby Laser Treatment of Solar Lentigines in Two Different Fitzpatrick Skin Types II and IV Completed NCT00386204 Phase 2
14 A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma Completed NCT00243061 Phase 2 cediranib maleate
15 Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face - Study PICAMEL Recruiting NCT02723721 Phase 2 Picato gel
16 A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
17 Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma Terminated NCT01120275 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
18 A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma Completed NCT00005057 Phase 1 ganciclovir
19 Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion. Unknown status NCT01136629
20 Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011 on Solar Lentigines by Harmonic Generation Microscopy Unknown status NCT01249469
21 A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation Unknown status NCT03421691
22 Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment Unknown status NCT03424148
23 The Role of Dermoscopy in Diagnosis of Pigmentary Skin Lesions Unknown status NCT03542539
24 Study for the RevLite Laser System for Facial Solar Lentigines Completed NCT02110108
25 A Single-Center 2-Arm Study of the Enlighten and Excel V Laser for Lentigines on the Hands Completed NCT02763072
26 Clinical Evaluation of the Performance of a Difluoroethane-based Cyto-selective Cryotherapy to Treat Dark Spots on the Hand in 30 Volunteers. Completed NCT03157427
27 Comparative Study Investigating the Therapy of of Solar Lentigines With the Q-switched SINON Rubin 694nm Laser Versus Pigmanorm® Cream Completed NCT02153697 Pigmanorm Cream
28 A Prospective Multi-Center Study of a Novel Dual-Wavelength, Dual-Pulse Duration Laser for the Treatment of Melasma and Lentigines in Asian Skin Completed NCT02385994
29 Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy. Completed NCT01778179 Tri-luma
30 Safety and Efficacy of Cutera Picosecond Q-Switched Nd:YAG Laser in the Treatment of Solar Lentigines Completed NCT01885871
31 Prospective Clinical Trial to Assess the Performance of a Cyto-selective Cryotherapye "CRYOBEAUTY MAINS ET DECOLLETE" Compared With Liquid Nitrogen Cryotherapy in the Treatment of Solar Lentigines in 30 Patients Completed NCT03225729
32 Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study Completed NCT02492373 topical 0.05% Clobetasol propionate ointment
33 Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy Completed NCT03457246
34 Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna Completed NCT00707174 Imiquimod Cream;Tazarotene Cream 0.1%
35 In Vivo Reflectance Confocal Microscopy for Pigmented Lesion Diagnosis: A Multi-center Study Completed NCT00785369
36 Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients Completed NCT01905891
37 Effectiveness, Safety, and Cost Efficacy of Water (H2O) as a Substitute for Sodium Bicarbonate (NaHCO3) Plus Solution in Neutralization of Chemical Peeling Using 35% Glycolic Acid Solution Completed NCT04154436
38 Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions Completed NCT00001452
39 Clinical and Histological Analysis of Photoaging Treatment With Imiquimod Cream 5% Completed NCT01935310 Imiquimod
40 Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder Recruiting NCT03578315
41 Reflectance Confocal Microscopy to Diagnose Malignant Melanoma and Lentigo Maligna Recruiting NCT03508297
42 Melanoma Family Case-Control Study Protocol Recruiting NCT00445783
43 Investigation Into the Natural History and Metabolic and Molecular Basis of RASopathies. Recruiting NCT04395495
44 Studies of Familial Melanoma Recruiting NCT00450593
45 The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser Active, not recruiting NCT02427724 lidocaine 2.5%/prilocaine 2.5% topical anesthetic;lidocaine 7%/tetracaine 7% topical anesthetic;placebo vehicle
46 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous Tumors Not yet recruiting NCT04068155
47 Open Label, Prospective, Single-Center Pilot Study to Evaluate the Effect of Multiple Passes on Port Wine Stain Treatments With the Cutera Excel V™ Laser. Suspended NCT04103164
48 Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence Withdrawn NCT02306512

Search NIH Clinical Center for Lentigines

Genetic Tests for Lentigines

Anatomical Context for Lentigines

MalaCards organs/tissues related to Lentigines:

40
Skin, Lymph Node, Heart, Bone, Breast, Colon, Cervix

Publications for Lentigines

Articles related to Lentigines:

(show top 50) (show all 2389)
# Title Authors PMID Year
1
A pedigree of generalized lentigo. 56 61
15422118 1950
2
A novel PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease and the Carney complex. 61 54
19833579 2010
3
PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link? 61 54
19582499 2009
4
Heterogeneity of skin manifestations in patients with Carney complex. 54 61
18804312 2008
5
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. 61 54
18470943 2008
6
Polymorphism patterns in the promoter region of the MC1R gene are associated with development of freckles and solar lentigines. 61 54
18079748 2008
7
Effect of Val92Met and Arg163Gln variants of the MC1R gene on freckles and solar lentigines in Japanese. 54 61
17371441 2007
8
PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype". 61 54
16733669 2006
9
Association between endothelin receptor B nonsynonymous variants and melanoma risk. 61 54
16145050 2005
10
A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. 61 54
15470362 2004
11
Clinical and molecular genetics of primary pigmented nodular adrenocortical disease. 61 54
15761532 2004
12
c-kit Mutation in generalized lentigines associated with gastrointestinal stromal tumor. 54 61
15118370 2004
13
Clinical and molecular genetics of Carney complex. 61 54
12666684 2003
14
PTPN11 mutations in LEOPARD syndrome. 61 54
12161596 2002
15
The melanocortin-1-receptor gene is the major freckle gene. 61 54
11487574 2001
16
Genetics of Peutz-Jeghers syndrome, Carney complex and other familial lentiginoses. 54 61
11595829 2000
17
Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants. 61
32233106 2020
18
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. 61
32240795 2020
19
Dermoscopic predictors to discriminate between in situ and early invasive lentigo maligna melanoma: A retrospective observational study. 61
32199898 2020
20
Atypical cardiac defects in patients with RASopathies: Updated data on CARNET study. 61
32558384 2020
21
Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic: What it whispers to us? 61
32530503 2020
22
Melanoma in Noonan Syndrome With Multiple Lentigines (Leopard Syndrome): A New Case. 61
32531240 2020
23
Generalized lentigines associated with familial gastrointestinal stromal tumors dramatically improved by imatinib treatment. 61
32220019 2020
24
Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. 61
31258001 2020
25
Lentigo Maligna Melanoma In-Situ with Neurotropism. 61
32557727 2020
26
Clinical, environmental, and histological distribution of BRAF, NRAS and TERT promoter mutations among cutaneous melanoma patients. A retrospective study of 563 patients. 61
32506424 2020
27
Reflectance confocal microscopy. Part II. Diagnostic criteria of common benign and malignant neoplasms, dermoscopic and histopathological correlates of key confocal criteria, and diagnostic algorithms. 61
32565210 2020
28
Junctional Melanocytic Hyperplasia Overlying Benign Fibrous Papule: An Under-recognized Variant of a Common Lesion. 61
32496596 2020
29
Cutaneous Head and Neck Melanoma: Changes in Clinical and Histologic Features From 1995 to 2015 in a Tertiary Hospital in Madrid, Spain. 61
32540035 2020
30
Successful Treatment of Pigmentary Disorders in Asians With a Novel 730-nm Picosecond Laser. 61
32410249 2020
31
Reflectance Confocal Microscopy of Pigmented Bowen's Disease: A Case Series of Difficult to Diagnose Lesions. 61
32518541 2020
32
[Voriconazole-induced lentigines on photo-exposed skin: A little-known complication]. 61
32414507 2020
33
Cryopeeling versus trichloroacetic acid peeling in the treatment of solar lentigines: Effect on epidermal Langerhans cells. 61
32118343 2020
34
Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines. 61
31378928 2020
35
A cross-sectional analysis of skin cancer risk in patients receiving narrow-band ultraviolet B phototherapy: an evaluation of 100 patients. 61
31729594 2020
36
In Vitro Methods to Simulate Pollution and Photo-Pollution Exposure in Human Skin Epidermis. 61
32447580 2020
37
[Noonan syndrome: genetic and clinical update and treatment options]. 61
32493603 2020
38
Superficial dermal melanocytosis of the elderly: An exceptional occurrence? 61
32388873 2020
39
Anti-melanogenic activity of salacinol by inhibition of tyrosinase oligosaccharide processing. 61
31883005 2020
40
The anatomic distribution of cutaneous melanoma: A detailed study of 5141 lesions. 61
31880825 2020
41
Epidermal keratin 5 expression and distribution is under dermal influence. 61
31692218 2020
42
Lentigo maligna in a patient with xeroderma pigmentosum, variant type: A case report with dermoscopic findings and review of the literature. 61
32379927 2020
43
Staged Excision With Micrographic Monitoring of Margins in Lentigo Maligna. 61
32471553 2020
44
A case of recurrent lentigo maligna diagnosed with precise reflectance confocal microscopy-guided biopsy technique. 61
32382627 2020
45
Should topical imiquimod be used for positive margins in lentigo maligna? 61
32387661 2020
46
Benefits of Teledermatology for Geriatric Patients: Population-Based Cross-Sectional Study. 61
32314966 2020
47
Pigmented spots on the lacrimal caruncle: a key to the diagnosis of Carney complex in a child with multiple lentigines. 61
32301134 2020
48
The clinical and electron microscopic evaluation of the impact of pulsed dye laser techniques on solar lentigines (randomized clinical trial). 61
32281430 2020
49
Lentigo maligna: diagnosis and treatment. 61
29683288 2020
50
Clinicopathologic diversity and outcome of longitudinal melanonychia in children and adolescents: Analysis of 35 cases identified by excision specimens. 61
32314423 2020

Variations for Lentigines

Expression for Lentigines

Search GEO for disease gene expression data for Lentigines.

Pathways for Lentigines

Pathways related to Lentigines according to GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.26 STK11 RAF1 PTPN11 PRKAR1A POMC MEN1
2
Show member pathways
13.92 STK11 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT
3
Show member pathways
13.81 RAF1 PTPN11 POMC MAP2K2 MAP2K1 KIT
4
Show member pathways
13.65 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT FGFR2
5
Show member pathways
13.63 RAF1 PTPN11 MAP2K2 MAP2K1 KIT FGFR2
6
Show member pathways
13.59 RAF1 PTPN11 MAP2K2 MAP2K1 KIT FGFR2
7
Show member pathways
13.42 RAF1 PTPN11 POMC MAP2K2 MAP2K1 KIT
8
Show member pathways
13.41 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT FGFR2
9
Show member pathways
13.37 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT FGFR2
10
Show member pathways
13.17 RAF1 MAP2K2 MAP2K1 KIT FGFR2 FGF7
11
Show member pathways
13.15 STK11 RAF1 PRKAR1A MAP2K2 MAP2K1 BRAF
12
Show member pathways
13.13 RAF1 PRKAR1A POMC MAP2K2 MAP2K1 BRAF
13
Show member pathways
13.1 STK11 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT
14
Show member pathways
13.08 STK11 RAF1 MAP2K2 MAP2K1 KIT FGFR2
15
Show member pathways
13 RAF1 PTPN11 PRKAR1A MAP2K2 MAP2K1 BRAF
16
Show member pathways
12.98 STK11 RAF1 MITF MAP2K2 MAP2K1 BRAF
17
Show member pathways
12.97 RAF1 PRKAR1A MAP2K2 MAP2K1 FGFR2 BRAF
18
Show member pathways
12.93 RAF1 PTPN11 MAP2K2 MAP2K1 KIT FGFR2
19
Show member pathways
12.92 RAF1 MAP2K2 MAP2K1 KIT EDNRB BRAF
20
Show member pathways
12.89 RAF1 PRKAR1A MAP2K2 MAP2K1 BRAF
21
Show member pathways
12.86 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
22
Show member pathways
12.81 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
23
Show member pathways
12.8 RAF1 MAP2K2 MAP2K1 KIT FGFR2 FGF7
24
Show member pathways
12.77 RAF1 POMC MAP2K2 MAP2K1 EDNRB
25
Show member pathways
12.76 RAF1 PRKAR1A MAP2K2 MAP2K1 BRAF
26
Show member pathways
12.76 RAF1 PRKAR1A MAP2K2 MAP2K1 BRAF
27 12.72 RAF1 MAP2K2 MAP2K1 FGFR2 FGF7 BRAF
28
Show member pathways
12.7 RAF1 PTPN11 MAP2K2 MAP2K1 FGFR2 BRAF
29
Show member pathways
12.69 RAF1 MITF MAP2K2 MAP2K1 FGFR2 FGF7
30
Show member pathways
12.68 RAF1 PTPN11 PRKAR1A MAP2K2 MAP2K1
31 12.64 RAF1 PTPN7 MAP2K2 MAP2K1 KIT FGFR2
32
Show member pathways
12.62 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
33
Show member pathways
12.57 STK11 RAF1 MAP2K2 MAP2K1 FGFR2 BRAF
34
Show member pathways
12.57 RAF1 PTPN11 MAP2K2 MAP2K1 KIT FGFR2
35
Show member pathways
12.56 RAF1 MAP2K2 MAP2K1 BRAF
36
Show member pathways
12.55 RAF1 PTPN11 MAP2K2 MAP2K1
37
Show member pathways
12.53 RAF1 PTPN11 MAP2K2 MAP2K1
38
Show member pathways
12.53 RAF1 MITF MAP2K2 MAP2K1 BRAF
39 12.53 RAF1 MITF MAP2K2 MAP2K1 KIT FGFR2
40
Show member pathways
12.52 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
41
Show member pathways
12.51 RAF1 PTPN11 MAP2K2 MAP2K1 KIT
42
Show member pathways
12.51 RAF1 PTPN11 MAP2K2 MAP2K1 BRAF
43
Show member pathways
12.49 STK11 PTPN11 FGFR2 FGF7
44
Show member pathways
12.48 RAF1 PTPN11 MAP2K2 MAP2K1
45
Show member pathways
12.48 RAF1 PRKAR1A MAP2K2 MAP2K1 BRAF
46
Show member pathways
12.45 RAF1 MAP2K2 MAP2K1 KIT FGFR2 FGF7
47 12.44 RAF1 POMC MAP2K2 MAP2K1 BRAF
48
Show member pathways
12.42 RAF1 MAP2K2 MAP2K1 BRAF
49
Show member pathways
12.42 RAF1 MAP2K2 MAP2K1 BRAF
50
Show member pathways
12.41 RAF1 PRKAR1A MAP2K2 MAP2K1

GO Terms for Lentigines

Cellular components related to Lentigines according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TYR STK11 SASH1 RAF1 PTPN7 PTPN11
2 cytoplasmic side of plasma membrane GO:0009898 9.13 PTPN7 MAP2K2 KIT

Biological processes related to Lentigines according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 intracellular signal transduction GO:0035556 9.99 RAF1 PRKAR1A MC1R KIT BRAF
2 protein phosphorylation GO:0006468 9.95 STK11 RAF1 MAP2K2 MAP2K1 KIT FGFR2
3 heart development GO:0007507 9.93 RAF1 PTPN11 PRKAR1A MAP2K1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.9 PTPN11 MAP2K1 FGFR2 BRAF
5 axonogenesis GO:0007409 9.83 STK11 PTPN11 FGFR2
6 activation of protein kinase activity GO:0032147 9.83 STK11 MAP2K2 MAP2K1
7 activation of MAPK activity GO:0000187 9.8 PTPN11 MAP2K2 MAP2K1 KIT
8 fibroblast growth factor receptor signaling pathway GO:0008543 9.79 PTPN11 FGFR2 FGF7
9 positive regulation of protein kinase B signaling GO:0051897 9.77 PTPN11 MC1R KIT FGFR2 FGF7
10 phosphorylation GO:0016310 9.76 STK11 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT
11 somatic stem cell population maintenance GO:0035019 9.75 RAF1 KIT BRAF
12 peptidyl-tyrosine phosphorylation GO:0018108 9.72 MAP2K2 MAP2K1 KIT FGFR2 BRAF
13 positive regulation of axonogenesis GO:0050772 9.7 STK11 MAP2K1 BRAF
14 melanin biosynthetic process GO:0042438 9.65 TYR MC1R
15 thyroid gland development GO:0030878 9.65 RAF1 MAP2K1 BRAF
16 branching involved in salivary gland morphogenesis GO:0060445 9.64 FGFR2 FGF7
17 developmental pigmentation GO:0048066 9.64 KIT EDNRB
18 organ growth GO:0035265 9.63 PTPN11 FGFR2
19 melanocyte differentiation GO:0030318 9.63 MITF KIT EDNRB
20 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 MAP2K2 MAP2K1
21 regulation of stress-activated MAPK cascade GO:0032872 9.61 MAP2K2 MAP2K1
22 Bergmann glial cell differentiation GO:0060020 9.61 PTPN11 MAP2K1
23 face development GO:0060324 9.61 RAF1 MAP2K1 BRAF
24 regulation of early endosome to late endosome transport GO:2000641 9.58 MAP2K2 MAP2K1
25 regulation of axon regeneration GO:0048679 9.57 MAP2K1 BRAF
26 positive regulation of epithelial cell proliferation involved in lung morphogenesis GO:0060501 9.56 FGFR2 FGF7
27 thymus development GO:0048538 9.56 TYR RAF1 MAP2K1 BRAF
28 myeloid progenitor cell differentiation GO:0002318 9.55 KIT BRAF
29 regulation of Golgi inheritance GO:0090170 9.54 MAP2K2 MAP2K1
30 cerebellar cortex formation GO:0021697 9.51 PTPN11 MAP2K1
31 pigmentation GO:0043473 9.35 TYR MITF MC1R KIT EDNRB
32 MAPK cascade GO:0000165 9.23 RAF1 MEN1 MAP2K2 MAP2K1 KIT FGFR2

Molecular functions related to Lentigines according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TYR STK11 SASH1 RAF1 PTPN7 PTPN11
2 nucleotide binding GO:0000166 10.01 STK11 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT
3 protein serine/threonine kinase activity GO:0004674 9.72 STK11 RAF1 MAP2K2 MAP2K1 BRAF
4 protein kinase activity GO:0004672 9.7 STK11 RAF1 MAP2K2 MAP2K1 KIT FGFR2
5 MAP-kinase scaffold activity GO:0005078 9.43 MAP2K2 MAP2K1
6 scaffold protein binding GO:0097110 9.43 MAP2K2 MAP2K1 BRAF
7 protein tyrosine kinase activity GO:0004713 9.35 MAP2K2 MAP2K1 KIT FGFR2 BRAF
8 kinase activity GO:0016301 9.23 STK11 RAF1 PRKAR1A MAP2K2 MAP2K1 KIT

Sources for Lentigines

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....